BR112021025161A2 - Anticorpo anti-epha4 - Google Patents

Anticorpo anti-epha4

Info

Publication number
BR112021025161A2
BR112021025161A2 BR112021025161A BR112021025161A BR112021025161A2 BR 112021025161 A2 BR112021025161 A2 BR 112021025161A2 BR 112021025161 A BR112021025161 A BR 112021025161A BR 112021025161 A BR112021025161 A BR 112021025161A BR 112021025161 A2 BR112021025161 A2 BR 112021025161A2
Authority
BR
Brazil
Prior art keywords
epha4
antibody
epha4 antibody
mouse anti
cleavage
Prior art date
Application number
BR112021025161A
Other languages
English (en)
Inventor
Aki Nakatani
Akio Yamada
Eiji Inoue
Maki Deguchi
Tomomi Kawakatsu
Toshio Imai
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112021025161A2 publication Critical patent/BR112021025161A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors

Abstract

anticorpo anti-epha4. trata-se de um anticorpo anti-epha4 que se liga a epha4 e melhora a clivagem de epha4, assim como uma composição farmacêutica que compreende o anticorpo como o ingrediente ativo. um anticorpo anti-epha4 de camundongo que tem afinidade de ligação para epha4 e pode melhorar a clivagem de epha4 foi obtido, e a sequência da região determinante de complementaridade (cdr) do anticorpo anti-epha4 de camundongo foi identificada. subsequentemente, o anticorpo anti-epha4 de interesse foi obtido produzindo-se um anticorpo humanizado do anticorpo anti-epha4 de camundongo.
BR112021025161A 2019-07-01 2020-06-29 Anticorpo anti-epha4 BR112021025161A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019122982 2019-07-01
PCT/JP2020/025465 WO2021002312A1 (ja) 2019-07-01 2020-06-29 抗ＥｐｈＡ４抗体

Publications (1)

Publication Number Publication Date
BR112021025161A2 true BR112021025161A2 (pt) 2022-01-25

Family

ID=74066003

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025161A BR112021025161A2 (pt) 2019-07-01 2020-06-29 Anticorpo anti-epha4

Country Status (20)

Country Link
US (2) US10947313B2 (pt)
EP (1) EP3995582A4 (pt)
JP (2) JP6979147B2 (pt)
KR (1) KR20220027825A (pt)
CN (2) CN113906050B (pt)
AR (1) AR119303A1 (pt)
AU (1) AU2020300205A1 (pt)
BR (1) BR112021025161A2 (pt)
CA (1) CA3139398A1 (pt)
CL (1) CL2021003326A1 (pt)
CO (1) CO2021016588A2 (pt)
IL (1) IL287828A (pt)
JO (1) JOP20210333A1 (pt)
MA (1) MA56466A (pt)
MX (1) MX2021015298A (pt)
PE (1) PE20220570A1 (pt)
SG (1) SG11202112433VA (pt)
TW (3) TWI779307B (pt)
WO (1) WO2021002312A1 (pt)
ZA (1) ZA202108836B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3995582A4 (en) 2019-07-01 2023-01-18 Eisai R&D Management Co., Ltd. ANTI-EPHA4 ANTIBODIES
CA3195085A1 (en) * 2020-12-24 2022-06-30 Eisai R&D Management Co., Ltd. Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis
CA3235297A1 (en) * 2021-11-11 2023-05-19 Eisai R&D Management Co., Ltd. Anti-epha4 antibody

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1094731A (en) 1911-06-06 1914-04-28 Lucien Linden Oxidizing process.
JP2824433B2 (ja) 1988-12-09 1998-11-11 財団法人化学及血清療法研究所 新規なハイブリッドプロモーターおよびこれを組み込んだ外来遺伝子発現用ベクター
CA1339413C (en) 1988-06-24 1997-09-02 Junichi Miyazaki Exogenous gene expression vector containing chick .beta.-actin gene promoter
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5902732A (en) 1995-10-04 1999-05-11 Cytoscan Sciences Llc Drug screening process measuring changes in cell volume
US20020068361A1 (en) 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
WO1998045708A1 (en) 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US5876946A (en) 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
US20060241074A1 (en) 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
US20070026409A1 (en) 2001-08-14 2007-02-01 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
CA2457819A1 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
JP2003169699A (ja) 2001-12-10 2003-06-17 Japan Science & Technology Corp 特異的γプロテアーゼ阻害剤のスクリーニング方法
JP2004000060A (ja) 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
WO2004028551A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
AU2003283619A1 (en) 2002-11-26 2004-06-18 Pharmacia & Upjohn Company Soluble notch-based substrates for gamma secretase and methods and compositions for using same
CA2528549A1 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer
WO2005045028A1 (ja) 2003-11-10 2005-05-19 Osaka Industrial Promotion Organization セル・フリー・Ｎｏｔｃｈ切断分析方法及び薬剤スクリーニング方法
US20070253954A1 (en) 2004-02-27 2007-11-01 Oncotherapy Science, Inc. Epha4 As Therapeutic Target Of Prc And Pdaca
EP1793854A4 (en) 2004-09-08 2008-01-02 Univ Queensland PROCESSING METHOD AND AGENTS USEFUL THEREFOR
EP1662259A1 (en) 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
GB0427023D0 (en) 2004-12-09 2005-01-12 Merck Sharp & Dohme Assay method
JP2009531273A (ja) 2006-02-28 2009-09-03 オンコセラピー・サイエンス株式会社 抗ＥｐｈＡ４抗体のエフェクター機能を用いて細胞を障害する方法
EP1947193A1 (en) 2007-01-17 2008-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening method for anti-diabetic compounds
US7910324B2 (en) 2007-06-08 2011-03-22 Eisai R&D Management Co., Ltd. Method of screening for compounds which affect the processing of EphA4 by γ-secretase
EP2183598A1 (en) 2007-07-13 2010-05-12 Elan Pharmaceuticals Inc. Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
US20090191580A1 (en) 2007-07-19 2009-07-30 Eisai R & D Management Co., Ltd. METHOD OF SCREENING USING c-MET, A NOVEL SUBSTRATE FOR GAMMA-SECRETASE
EP2192181A4 (en) 2007-08-01 2010-12-08 Eisai R&D Man Co Ltd SCREENING METHOD USING THE NEW C-RET SUBSTRATE FOR GAMMA-SECRETASE
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
US20090163594A1 (en) 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
EP2219028B1 (en) 2007-11-15 2012-09-12 Eisai R&D Management Co., Ltd. Screening method utilizing novel substrate epha7 for gamma-secretase
EP2223999B1 (en) 2007-11-30 2017-10-18 Eisai R&D Management Co., Ltd. Epha4 polypeptide having novel activity and use thereof
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP2260864A1 (en) 2009-06-10 2010-12-15 University of Melbourne Therapeutic applications
JP2010285413A (ja) 2009-06-10 2010-12-24 Univ Of Melbourne 治療用途
WO2012081502A1 (ja) 2010-12-17 2012-06-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法
EP2703814B1 (en) 2011-04-25 2017-11-01 Eisai R&D Management Co., Ltd. Method for detecting neurological disease associated with cognitive dysfunction by measuring epha4 extracellular domain
GB201107996D0 (en) 2011-05-13 2011-06-29 Vib Vzw EphA4 is a diease modifier in motor neuron disease
JP6811706B2 (ja) 2014-07-31 2021-01-13 ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用
KR20180041136A (ko) * 2015-09-08 2018-04-23 에자이 알앤드디 매니지먼트 가부시키가이샤 항-epha4 항체
EP3995582A4 (en) 2019-07-01 2023-01-18 Eisai R&D Management Co., Ltd. ANTI-EPHA4 ANTIBODIES

Also Published As

Publication number Publication date
JP2022031271A (ja) 2022-02-18
KR20220027825A (ko) 2022-03-08
JP6979147B2 (ja) 2021-12-08
EP3995582A1 (en) 2022-05-11
MA56466A (fr) 2022-05-11
CN113906050A (zh) 2022-01-07
JPWO2021002312A1 (ja) 2021-09-13
TWI808882B (zh) 2023-07-11
CN117398459A (zh) 2024-01-16
US20210002378A1 (en) 2021-01-07
TW202342101A (zh) 2023-11-01
US20210171644A1 (en) 2021-06-10
AU2020300205A1 (en) 2022-01-20
CO2021016588A2 (es) 2022-04-08
CN113906050B (zh) 2023-11-21
ZA202108836B (en) 2023-04-26
TW202248216A (zh) 2022-12-16
CA3139398A1 (en) 2021-01-07
IL287828A (en) 2022-01-01
US11136400B2 (en) 2021-10-05
TW202115116A (zh) 2021-04-16
US10947313B2 (en) 2021-03-16
MX2021015298A (es) 2022-01-18
PE20220570A1 (es) 2022-04-20
WO2021002312A1 (ja) 2021-01-07
EP3995582A4 (en) 2023-01-18
JOP20210333A1 (ar) 2023-01-30
AR119303A1 (es) 2021-12-09
CL2021003326A1 (es) 2022-07-22
TWI779307B (zh) 2022-10-01
JP7072114B2 (ja) 2022-05-19
SG11202112433VA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
BR112021025161A2 (pt) Anticorpo anti-epha4
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
CO2021008696A2 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
BR112017020413A2 (pt) ?anticorpo anti-notch4 humano?
BR112018076260A2 (pt) anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
ECSP20020111A (es) Anticuerpos de b7-h4 y métodos para usarlos
BR112018002570A2 (pt) molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
CL2022003027A1 (es) Anticuerpo anti-transtiretina (ttr); composición farmacéutica; ácido nucleico; vector; célula; método para humanizar un anticuerpo; método
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
EA201692458A1 (ru) Анти-gitr антитела и способы их применения
BR112018006350A2 (pt) anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, formulação farmacêutica e uso do anticorpo
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA202192405A1 (ru) Составы антител против il-36r
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
UY37457A (es) Compuestos de anticuerpos acoplados de tirosina-tirosina cíclica como moduladores de receptores del neuropeptido y
CL2022003515A1 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2
BR112018003494A2 (pt) anticorpo anti-epha4
MX2020009275A (es) Composiciones de anticuerpo anti-pd-1.
EA201992027A1 (ru) Водный состав антитела против pd-l1
MX2021004774A (es) Formulacion de anticuerpos.
BR112017007877A2 (pt) anticorpo ou fragmento do mesmo, epítopo em ccr6 humana solúvel, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição e imunoconjugado
CO2023013543A2 (es) Anticuerpos anti-cd20 y estructuras car-t
BR112017019075A2 (pt) anticorpo anti-esclerostina, fragmento de ligação ao antígeno e uso médico desses
CO2020015124A2 (es) Anticuerpo anti-tlr7 humano